CPT® Code 87515

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, direct probe technique

Common Language Description

The CPT® Code 87515 refers to a laboratory test designed for the detection of the hepatitis B virus (HBV) through the analysis of nucleic acids, specifically DNA or RNA. This test employs a direct probe technique, which is a method used to identify specific sequences of nucleic acids associated with the virus. Hepatitis B is a significant public health concern, as chronic infection can lead to severe complications such as cirrhosis of the liver and hepatocellular carcinoma, a type of liver cancer. The virus is primarily transmitted through blood and body fluids, which can occur during sexual contact, from mother to child during childbirth, or through shared contaminated items like needles and personal grooming tools. Patients infected with HBV may experience a range of symptoms, including fever, fatigue, abdominal discomfort, weight loss, nausea or vomiting, and joint pain; however, some individuals may remain asymptomatic. The ability to detect HBV nucleic acid is particularly valuable, especially in cases where hepatitis B surface Antigen (HBsAg) tests return negative results, as it can provide critical prognostic information regarding the infection. The test requires a blood sample, from which serum or plasma is extracted for analysis. It is important to note that while the direct probe technique is useful, it may yield false negative results if the viral load is low. For more sensitive detection, alternative codes such as 87516 and 87517 are available, which utilize amplified probe methods and quantification of viral load, respectively. Overall, CPT® Code 87515 is essential for the accurate diagnosis and management of hepatitis B infections.

1. Indications

The CPT® Code 87515 is indicated for the detection of the hepatitis B virus (HBV) in patients who may be at risk for infection or who exhibit symptoms associated with hepatitis B. The following conditions and situations warrant the use of this test:

Chronic HBV Infection Individuals with a known history of chronic hepatitis B infection, as they are at increased risk for complications such as cirrhosis and hepatocellular carcinoma.
Asymptomatic Individuals Patients who may be asymptomatic but are at risk for HBV infection due to potential exposure through blood or body fluids.
Negative HBsAg Results Cases where hepatitis B surface Antigen (HBsAg) tests return negative results, yet there is a clinical suspicion of active HBV infection.
Monitoring Viral Load Patients undergoing treatment for HBV who require monitoring of viral replication levels to assess disease progression and response to therapy.

2. Procedure

The procedure for CPT® Code 87515 involves several key steps to ensure accurate detection of the hepatitis B virus nucleic acid. The following procedural steps are outlined:

Step 1: Sample Collection A blood sample is collected from the patient, typically via venipuncture. This sample is essential for the subsequent analysis of serum or plasma to detect the presence of HBV nucleic acid.
Step 2: Sample Preparation The collected blood sample is processed to separate the serum or plasma, which is then prepared for testing. This preparation is crucial to isolate the nucleic acids that will be analyzed for the presence of HBV.
Step 3: Direct Probe Technique The direct probe technique is employed to detect the specific nucleic acid sequences associated with the hepatitis B virus. This method involves the use of labeled probes that bind to the target HBV DNA or RNA, allowing for identification and quantification.
Step 4: Result Interpretation After the analysis is complete, the results are interpreted by laboratory personnel. The presence of HBV nucleic acid indicates an active infection, while the absence may suggest a lack of viral replication, although false negatives can occur with low viral loads.

3. Post-Procedure

Post-procedure care for patients undergoing the CPT® Code 87515 test is generally minimal, as it is a laboratory test that does not require invasive intervention. However, it is important for healthcare providers to communicate the following considerations to patients:

Patients should be informed about the potential for false negative results, particularly if their viral load is low. They may need to undergo additional testing or follow-up assessments if symptoms persist or if there is a high suspicion of HBV infection despite negative results. Additionally, healthcare providers should discuss the implications of the test results, including the need for further monitoring or treatment options if HBV is detected. Overall, the results of the test play a critical role in guiding clinical decisions and managing the patient's health regarding hepatitis B infection.

Short Descr	HEPATITIS B DNA DIR PROBE
Medium Descr	IADNA HEPATITIS B VIRUS DIRECT PROBE TECHNIQUE
Long Descr	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, direct probe technique
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Conditionally packaged laboratory tests
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	Not applicable/unspecified.
CCS Clinical Classification	206 - Microscopic examination (bacterial smear, culture, toxicology)